Can the intravenous (IV) formulation of Keppra (levetiracetam) be given orally?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can You Give Keppra IV Formulation Orally?

Yes, the intravenous formulation of Keppra (levetiracetam) can be given orally, though this is an off-label use not specifically addressed in FDA labeling.

Evidence Supporting Oral Administration of IV Formulation

The FDA label for Keppra IV explicitly states that it is "for intravenous use only as an alternative for patients when oral administration is temporarily not feasible" 1. However, the label also demonstrates that IV and oral formulations are bioequivalent - equivalent doses result in equivalent Cmax, Cmin, and total systemic exposure when IV levetiracetam is administered as a 15-minute infusion 1.

Research directly supports this practice: A bioequivalence study in healthy subjects found that single doses of levetiracetam 1,500 mg administered as a 15-minute IV infusion and as oral tablets were bioequivalent, with geometric mean IV/oral ratios of 92.2% for AUC and 103.7% for Cmax 2. Another study confirmed that 45-minute IV infusion and oral tablets were bioequivalent in healthy Chinese subjects 3.

Practical Considerations

The IV formulation is a concentrated solution that can be administered orally when:

  • Oral tablets are unavailable
  • The patient cannot swallow tablets but can take liquids
  • Rapid dose titration is needed and oral solution is not available

Key points for oral administration of IV formulation:

  • The bioavailability is essentially complete (near 100%)
  • No dose adjustment is needed when switching between routes 1
  • The tmax (time to peak concentration) is similar between oral tablets and IV formulation given over appropriate infusion times 3

Clinical Context from Guidelines

Emergency medicine guidelines recognize both oral and IV levetiracetam as acceptable routes for seizure management 4. The 2014 ACEP guidelines note that for antiepileptic medications in the ED, "there is a lack of evidence to support one route of administration (oral versus parenteral) over the other in terms of preventing early recurrent seizure" 4.

For loading doses, the guidelines recommend 1,500 mg oral load, with rapid IV loading safe and well tolerated in doses up to 60 mg/kg 4. The 2024 guidelines for status epilepticus recommend 30-50 mg/kg IV load at 100 mg/min 4, 5.

Important Caveats

  • This is an off-label use - the FDA label does not specifically authorize oral administration of the IV formulation
  • The IV formulation is significantly more expensive than oral tablets or oral solution
  • If oral administration is feasible, use the FDA-approved oral formulation (tablets or oral solution) rather than giving IV formulation orally
  • The practice should be reserved for situations where oral formulations are truly unavailable

Bottom line: While pharmacokinetically sound and supported by bioequivalence data, giving IV Keppra orally should only be done when oral formulations are unavailable, as it represents off-label use of a more expensive formulation.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.